Company Overview

ZYUS Life Sciences Corporation is a Canadian life sciences company focused on the development, production, and commercialization of cannabinoid-based and plant-derived biopharmaceutical and nutraceutical products. The company operates primarily in the medical cannabis, pharmaceutical research, and health sciences industries, with activities spanning drug development, clinical research, patient care, and cannabinoid ingredient manufacturing. ZYUS is publicly traded on the TSX Venture Exchange under the ticker ZYUS.V.

The company’s principal business lines include cannabinoid-based therapeutic development, medical cannabis patient services, bioscience research, and the production of pharmaceutical-grade cannabis formulations. ZYUS has positioned itself as a science-driven organization emphasizing standardized formulations, clinical validation, and physician-guided treatment approaches. The company traces its origins to medical cannabis research initiatives in Saskatchewan and evolved through acquisitions and partnerships that expanded its capabilities in cultivation, extraction, clinical development, and patient access services.

Business Operations

ZYUS conducts operations through integrated life sciences and cannabinoid-focused activities that include research and development, cultivation oversight, extraction, formulation, and patient-oriented healthcare services. Its revenue model has historically included medical cannabis product sales, patient consultation services, licensing-related activities, and pharmaceutical development initiatives. The company has emphasized controlled production standards and evidence-based cannabinoid therapies intended for regulated healthcare markets.

The company’s operations are centered primarily in Canada, with a focus on regulated medical channels and research partnerships. ZYUS has been associated with clinical collaborations involving healthcare practitioners, academic institutions, and pharmaceutical research organizations. Its controlled assets and operational capabilities include cannabinoid formulation technologies, extraction expertise, and intellectual property related to cannabinoid therapeutics. Public disclosures also reference relationships with healthcare and scientific organizations supporting product development and patient-care initiatives.

Strategic Position & Investments

ZYUS has pursued a strategy centered on pharmaceutical-grade cannabinoid therapies, differentiated from broader recreational cannabis market participants through its emphasis on clinical evidence and regulated medical applications. The company has invested in research programs involving cannabinoid-based treatments for neurological, inflammatory, and chronic health conditions. Its strategic direction has included efforts to expand intellectual property holdings, clinical trial participation, and physician-supported treatment models.

The company has also pursued acquisitions and investments intended to strengthen vertical integration and scientific capabilities. Public filings and corporate disclosures reference investments in cultivation infrastructure, extraction technologies, and healthcare service platforms. ZYUS has shown interest in emerging sectors involving biosciences, precision formulations, and cannabinoid pharmaceutical applications. Some development-stage initiatives referenced in corporate materials remain subject to regulatory review and commercialization milestones, and certain timelines are not independently verifiable from currently available public disclosures.

Geographic Footprint

ZYUS is headquartered in Saskatchewan, Canada, with operational activities concentrated primarily within the Canadian medical cannabis and life sciences sectors. The company’s research and healthcare collaborations have involved institutions and partners across multiple Canadian provinces, particularly in Western Canada. Its operational footprint reflects Canada’s federally regulated medical cannabis framework and pharmaceutical research environment.

While the company’s principal market presence remains domestic, ZYUS has expressed interest in international opportunities involving cannabinoid science and pharmaceutical applications. Public information indicates strategic awareness of potential markets in regions such as North America and selected international medical cannabis jurisdictions, though large-scale international commercial operations are not extensively documented in publicly available filings. Data regarding material international revenue exposure remains inconclusive based on available public sources.

Leadership & Governance

ZYUS leadership has emphasized a science-based and medically focused approach to cannabinoid therapeutics, with corporate strategy oriented toward clinical validation, regulatory compliance, and pharmaceutical-grade production standards. Governance oversight is provided through executive leadership and a board structure typical of publicly listed Canadian life sciences issuers.

Key executives and leadership figures identified in public disclosures include:

• Brent Zettl – Chairman and Chief Executive Officer
• Richard Findlay – Chief Financial Officer
• Stephen Lucas – President
• Michael Krestell – Chief Operating Officer

Leadership communications in public filings and investor materials consistently emphasize innovation in cannabinoid medicine, integration between healthcare and bioscience operations, and the advancement of evidence-supported therapeutic products. Certain executive roles and organizational structures may change over time, and investors typically rely on the company’s most recent regulatory filings and corporate disclosures for current governance details.